To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - ICU Medical reported fourth-quarter 2025 revenue of $536 million, achieving 2% organic growth and 5% organic growth for the full year, with record performance in consumables and infusion systems [4][7] - The company delivered adjusted EBITDA of $98 million and adjusted earnings per share of $1.91, with gross margins remaining above 40% [3][7] - The 2026 outlook anticipates low- to mid-single-digit organic growth, adjusted EBITDA of $400–430 million, and adjusted EPS of $7.75–8.45, with a focus on improving free cash flow to reduce debt [5][15] Financial Performance - Adjusted SG&A expenses were reported at $113 million, and adjusted R&D expenses were $21 million, totaling adjusted operating expenses of $134 million, which is 25% of revenue [1] - The adjusted gross margin for the quarter was 40.5%, consistent with prior guidance of 40% to 41%, impacted by $11 million in tariff expenses [2][7] - Adjusted EBITDA declined 7% year-over-year from $106 million, primarily due to the deconsolidation of IV Solutions and tariff impacts, representing a $25 million EBITDA headwind [7] Business Segments - Consumables revenue grew 6% reported and 5% organic in Q4, with full-year growth of 7% reported and 6% organic, driven by strong demand in infusion consumables and oncology [8] - Infusion systems revenue increased 3% reported and 1% organic in Q4, with expectations of mid-single-digit organic growth in the near term [16] - Vital Care experienced a 6% organic decline and a 35% reported decline due to the IV Solutions deconsolidation, with management focusing on discontinuing loss-making SKUs [16] Regulatory and Integration Updates - The company closed a broad FDA warning letter related to Smiths Medical and completed major manufacturing and ERP integrations, which are expected to unlock synergies [6][11] - ICU Medical is pursuing 510(k) clearances for key products, including the Medfusion 5000 syringe pump and LifeShield software, as part of its strategy to enhance product offerings [10] 2026 Guidance and Strategic Focus - The company projects full-year adjusted gross margin of around 41%, with improvements expected throughout the year, despite manufacturing inflation and tariff expenses [14] - Free cash flow is expected to improve in 2026, with a focus on debt reduction and a long-term leverage target of 2x by early 2027 [18] - Management indicated that any strategic moves would need to avoid value destruction, particularly in the Critical Care segment, which is seen as less synergistic [19]

Core Viewpoint - ICU Medical reported a revenue of $535.94 million for the quarter ended December 2025, reflecting a 13.8% decline year-over-year, with an EPS of $1.91 compared to $2.11 in the same quarter last year [1] Financial Performance - The reported revenue of $535.94 million exceeded the Zacks Consensus Estimate of $528.97 million, resulting in a surprise of +1.32% [1] - The company achieved an EPS surprise of +13.52%, with the consensus EPS estimate being $1.68 [1] Key Metrics - Revenue from Infusion Systems was $176.3 million, slightly below the average estimate of $177.59 million from two analysts [4] - Revenue from Vital Care reached $79.7 million, surpassing the average estimate of $76.87 million from two analysts [4] - Revenue from Consumables was $284.7 million, exceeding the two-analyst average estimate of $280.64 million [4] Stock Performance - Shares of ICU Medical have returned -2.3% over the past month, compared to a -0.8% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

分组1 - ICU Medical reported quarterly earnings of $1.91 per share, exceeding the Zacks Consensus Estimate of $1.68 per share, but down from $2.11 per share a year ago, representing an earnings surprise of +13.52% [1] - The company achieved revenues of $535.94 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.32%, but down from $621.62 million year-over-year [2] - ICU Medical has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] 分组2 - The stock has gained approximately 6.3% since the beginning of the year, outperforming the S&P 500's gain of 0.5% [3] - The current consensus EPS estimate for the upcoming quarter is $1.78 on revenues of $522.55 million, and for the current fiscal year, it is $7.96 on revenues of $2.17 billion [7] - The Zacks Industry Rank for Medical - Products is currently in the bottom 40% of over 250 Zacks industries, which may impact stock performance [8]

ICU Medical (NasdaqGS:ICUI) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Company ParticipantsBrian Bonnell - CFOJayson Bedford - Managing Director of Medical TechnologyJohn Mills - Managing PartnerLarry Solow - PartnerVivek Jain - CEO and ChairmanConference Call ParticipantsBrett Fishbin - VP and Senior Equity Research AnalystJason Bednar - Senior Research AnalystMike Matson - Senior AnalystOperatorGood day, and welcome to the ICU Medical, Inc., fourth quarter 2025 earnings conference call. All parti ...

ICU Medical (NasdaqGS:ICUI) Q4 2025 Earnings call February 19, 2026 04:30 PM ET Company ParticipantsBrian Bonnell - CFOJayson Bedford - Managing Director of Medical TechnologyJohn Mills - Managing PartnerLarry Solow - PartnerVivek Jain - CEO and ChairmanConference Call ParticipantsBrett Fishbin - VP and Senior Equity Research AnalystJason Bednar - Senior Research AnalystMike Matson - Senior AnalystOperatorGood day, and welcome to the ICU Medical, Inc., fourth quarter 2025 earnings conference call. All parti ...

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $536 million, representing a 2% organic growth but a -14% reported decline, with full-year organic growth at 5% [4] - Gross margins were above 40%, with EBITDA of $98 million and EPS of $1.91, reflecting a year-over-year decline in EBITDA due to deconsolidation and tariffs [5][17] - Adjusted gross margin for Q4 was 40.5%, with adjusted EBITDA decreasing by 7% from $106 million last year [15][17] - Free cash flow for Q4 was $44 million, contributing to a total of $100 million for the year, slightly better than guidance [18][25] Business Line Data and Key Metrics Changes - Consumables business grew 6% reported and 5% organic in Q4, with full-year growth at 7% reported and 6% organic [6][7] - IV systems business grew 3% reported and 1% organic, with the best quarter in pumps despite some installations being pulled into Q3 [7][8] - Vital Care decreased 6% organically and 35% reported due to deconsolidation, remaining flat for the year [9] Market Data and Key Metrics Changes - The demand environment in Q4 was strong across most geographies, with a notable flu spike in the U.S. towards year-end [5] - The capital environment remained stable, with investments being executed as planned [6] Company Strategy and Development Direction - The company aims to create a comprehensive infusion therapy company, focusing on operational stability and innovation to improve performance in vascular access [6][31] - The strategy includes modernizing the IV solutions business through a joint venture with Otsuka and enhancing product offerings with FDA-cleared devices [30][32] - Long-term goals include achieving mid-single-digit growth in consumables and infusion systems, while Vital Care is expected to remain flat to slightly down [19][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operational improvements and expected benefits from completed integration projects, leading to better cash flow and margins [27][81] - The company anticipates challenges from tariffs and interest rates but believes it can overcome these hurdles to achieve original targets [28][33] Other Important Information - The company has made significant progress in integrating manufacturing sites and IT systems, which is expected to yield operational synergies [11][12] - The company plans to prioritize debt repayment with free cash flow generated in 2026, targeting a long-term leverage ratio of 2 times [26] Q&A Session Summary Question: Current environment for systems and customer decision-making - Management indicated that the capital environment is stable, with deals being executed as expected [39] Question: Impact of new product cycles and competitive landscape - Management noted that while competitive challenges exist, they are starting from a stronger position and expect to grow through existing headwinds [76] Question: Underlying volume trends in consumables - Management confirmed that underlying demand remains positive, despite some seasonal fluctuations [54] Question: Tariff mitigation efforts - Management stated that structural changes have been made to mitigate tariff impacts, with some benefits already seen in Q4 [57] Question: Potential sale of the critical care business - Management acknowledged the complexities involved in assessing the critical care business due to its integration with other operations [66]

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or | | | For the transition period from to Commission File No. 001-34634 ICU MEDICAL, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 33-0022692 (State or Other Jurisdiction of Incorporat ...

ICU Medical Q4 2025 Conference Call Presentation February 19, 2026 1 Disclosures 2 > Any statement concerning Management's expectation with respect to future results is a forward-looking statement based upon the best information currently available to Management and assumptions Management believes are reasonable, but Management does not intend the statement to be a representation as to future results. > Future results are subject to risks and uncertainties, including the risk factors described in the Compan ...

Exhibit 99.1 ICU Medical Announces Fourth Quarter 2025 Results and Provides Fiscal Year 2026 Guidance SAN CLEMENTE, Calif., February 19, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended December 31, 2025. Conference Call Fourth Quarter 2025 Results Fourth quarter 2025 revenue was $540.7 million, as compared to $629.8 million in the same period in the pri ...